Home > Featured Products > Model Organism > Canine

Canine (Canis lupus familiaris) Research Reagents

Browse Canine (Canis lupus familiaris) antibodies and recombinant proteins — species-validated for developmental biology, disease modeling, and comparative studies. RUO

Why Researchers Choose abinScience

Species-Specific Validation Antibodies validated with confirmed reactivity to your model organism using appropriate positive controls.

Broad Target Coverage Immune markers, signaling molecules, structural proteins, and disease-relevant biomarkers.

Cross-Reactivity Data Detailed species cross-reactivity information provided on every product datasheet.

Multiple Applications Validated for WB, IHC, IF, ELISA, and FC across veterinary, developmental, and comparative biology research.

Original Manufacturer In-house production with rigorous quality control — reliable supply and consistent quality.

Documents & QC Data

Download product datasheets, validation images (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

FAQs

How are your antibodies validated?

Every antibody is validated in its listed applications (WB, IHC, IF, ELISA, FC) with supporting images and data on the product page. We use positive and negative controls plus knockout/knockdown verification where available.

Do you offer conjugated antibodies?

Yes — HRP, AP, biotin, FITC, PE, APC, Alexa Fluor, and other fluorochrome conjugates are available. Custom conjugation services are also offered for bulk orders.

What species do your antibodies react with?

Most antibodies target human, mouse, and rat. Many show validated cross-reactivity with additional species. Check the product datasheet for confirmed reactivity data.

What is your replacement policy?

If a product does not perform as described under recommended conditions, contact us within 30 days for replacement or credit. Our technical team will help troubleshoot first.

Can I get custom antibodies?

Yes — our parent company AtaGenix offers full custom antibody development from immunogen design through hybridoma screening and scale-up production.